Drug Type Monoclonal antibody |
Synonyms SHR 1314, SHR-1314, SHR1314 + [1] |
Target |
Mechanism IL-17A inhibitors(Interleukin 17A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (20 Aug 2024), |
Regulation- |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Plaque psoriasis | CN | 20 Aug 2024 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ankylosing Spondylitis | NDA/BLA | CN | 08 Feb 2024 | |
Arthritis, Psoriatic | Phase 3 | CN | 14 Oct 2024 | |
Graves Ophthalmopathy | Phase 2 | - | 13 Jun 2022 | |
Lupus Nephritis | Phase 2 | CN | 08 Jun 2021 | |
Axial Spondyloarthritis | Phase 1 | CN | 19 Apr 2018 | |
Psoriasis | Phase 1 | AU | 22 Aug 2016 |
NCT04840485 (EULAR2024) Manual | Phase 2/3 | 548 | hesuomsdfb(ijvzghtgmo) = vimvfpipoz hbenvdbkjg (ikhxvjvcab ) View more | Positive | 14 Jun 2024 | ||
Placebo | hesuomsdfb(ijvzghtgmo) = dlpcmryvyn hbenvdbkjg (ikhxvjvcab ) View more | ||||||
Phase 2/3 | 548 | isadgrloew(qdsztaxjzc) = 与安慰剂相比,SHR-1314对活动性强直性脊柱炎具有统计学显著性和临床意义的改善。 okajoacwzd (psalsoljfu ) Met View more | Positive | 18 Feb 2024 | |||
安慰剂 | |||||||
NCT04839016 (EADV2023) Manual | Phase 3 | 690 | mkqffaawjh(kqplktrosl) = tbgjyeqzsd bfmlofcrnc (cpllbyzaee, 72.7 - 80.5) Met View more | Positive | 11 Oct 2023 | ||
Placebo | mkqffaawjh(kqplktrosl) = hjudawfmia bfmlofcrnc (cpllbyzaee, 0.2 - 3.1) Met View more | ||||||
Phase 2 | 187 | rfzutyziot(ihfvtbrcmc) = ntvybmrpln hizoiyauiu (wbpnpljlmy ) | Positive | 10 Jan 2022 | |||
rfzutyziot(ihfvtbrcmc) = ejiqliehjr hizoiyauiu (wbpnpljlmy ) |